Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Novo’s Growth Hormone, Teijin’s Osteoporosis Med Skip May Listing
May 13, 2021
- May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
- Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
- Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
May 12, 2021
- Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
- Kanmin Taiwa Public-Private Confab Set for May 17
May 11, 2021
- MHLW to Fund 7 Development Projects for COVID-19 Therapies
May 11, 2021
- Japan in Talks with 3 Vaccine Makers for Additional Supplies, Eyes 250 Million More Doses
May 10, 2021
- No Impact of Transport Seen on Comirnaty’s mRNA Content or Expression of Spike Proteins: NIHS Study
May 10, 2021
- New Industry Vision to Reaffirm Pharmaceuticals as Growth Industry: MHLW Director
April 30, 2021
- MHLW to Set New Generic Target of 80% in Every Prefecture by FY2023-End
April 30, 2021
- LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
April 30, 2021
- MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
- Bayer’s Heart Failure Med Now in Line for June Approval
April 30, 2021
- Large-Scale Vaccination Center to Open in Tokyo on May 24
April 28, 2021
- LDP Project Team Submits Proposal, Minister Vows to Subsidize Morning/Nighttime Vaccinations
April 28, 2021
- Rebuild Vaccine Development System as National Security: CEFP Members
April 27, 2021
- LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
April 27, 2021
- Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
April 26, 2021
- Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
April 26, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…